AI Generated Image
Insilico's co-CEO hopes 'we might have a chance to stop biological aging'
Fortune • • business
Key Points:
- The Asia-Pacific region faces a demographic shift, with one in four people expected to be over 60 by 2050, increasing strain on healthcare systems due to chronic conditions.
- AI drugmakers, like Insilico Medicine, are exploring treatments targeting biological aging, with early evidence suggesting their experimental fibrosis drug may reduce biological age by up to six years.
- Experts emphasize extending healthy life expectancy ("healthspan") rather than just lifespan, aiming to improve the quality of life and reduce years spent in poor health or disability.
- While new technologies promise life extension, healthcare affordability and accessibility remain major challenges, especially as populations age.
- Advances in medicine are transforming some terminal illnesses, such as cancer, into manageable chronic diseases, significantly extending patient survival times.
